Charles River joins Lilly TuneLab to optimize AI/ML platform through nonclinical testing expertise.

{
  "signal_id": "8a696ec5-8f5f-44fe-a276-fdb5c0a4d9c1",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-06-19T06:09:12+00:00",
  "company": {
    "name": "Charles River Laboratories",
    "domain": "crl.com"
  },
  "data": {
    "url": "https://www.pharmafocusasia.com/pressreleases/charles-river-joins-lilly-tunelab-to-optimize",
    "title": "Charles River joins Lilly TuneLab to optimize AI/ML platform through nonclinical testing expertise.",
    "excerpt": "Charles River joins Lilly TuneLab to optimize AI/ML platform through nonclinical testing expertise.\n\nFriday, June 19, 2026\n\nCharles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly).\n\nTuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data, in exchange for data contributions that improve model performance through federated learning. Participating companies may use the TuneLab prediction models to more rapidly down-select candidate molecules. Through this collaboration, Charles River will provide nonclinical testing services to TuneLab companies.\n\n\"The combination of Charles River's decades-long expertise in nonclinical testing with TuneLab's innovative AI/ML models will support the accelerated development of innovative therapeutics,\" said Dr. Namandjé N. Bumpus, Chief Science and Innovation Officer, Charles River. \"TuneLab's collaborative AI platform democratizes access to pharma-grade tools, relieving a substantial resource burden for biotechs. By layering in Charles River's industry-leading hands-on research experience, TuneLab participants have access to additional validation that supports discovery...",
    "summary": "Charles River Laboratories International partnered with Eli Lilly on Jun 19th '26.",
    "planning": false,
    "image_url": "https://industry.pharmafocusasia.com/images/logo.webp",
    "confidence": 0.8177,
    "published_at": "2026-06-19T06:09:12Z",
    "effective_date": "2026-06-19",
    "article_sentence": "Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly).",
    "related_company_name": "Eli Lilly",
    "related_company_domain": "lilly.com"
  }
}

curl https://signals.autobound.ai/v1/signals/8a696ec5-8f5f-44fe-a276-fdb5c0a4d9c1 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"crl.com","limit":20}'